- Open Access
PEGylating a bacteriophage endolysin inhibits its bactericidal activity
© Resch et al; licensee Springer. 2011
Received: 5 September 2011
Accepted: 7 October 2011
Published: 7 October 2011
Bacteriophage endolysins (lysins) bind to a cell wall substrate and cleave peptidoglycan, resulting in hypotonic lysis of the phage-infected bacteria. When purified lysins are added externally to Gram-positive bacteria they mediate rapid death by the same mechanism. For this reason, novel therapeutic strategies have been developed using such enzybiotics. However, like other proteins introduced into mammalian organisms, they are quickly cleared from systemic circulation. PEGylation has been used successfully to increase the in vivo half-life of many biological molecules and was therefore applied to Cpl-1, a lysin specific for S. pneumoniae. Cysteine-specific PEGylation with either PEG 10K or 40K was achieved on Cpl-1 mutants, each containing an additional cysteine residue at different locations To the best of our knowledge, this is the first report of the PEGylation of bacteriophage lysin. Compared to the native enzyme, none of the PEGylated conjugates retained significant in vitro anti-pneumococcal lytic activity that would have justified further in vivo studies. Since the anti-microbial activity of the mutant enzymes used in this study was not affected by the introduction of the cysteine residue, our results implied that the presence of the PEG molecule was responsible for the inhibition. As most endolysins exhibit a similar modular structure, we believe that our work emphasizes the inability to improve the in vivo half-life of this class of enzybiotics using a cysteine-specific PEGylation strategy.
Streptococcus pneumoniae is the first cause of otitis media and a common cause of sinusitis, community-acquired pneumonia, bacteremia, and meningitis (Jacobs, 2004). Antibiotic misuse and overuse has progressively selected for resistance against major drug classes, and treatment failures are widely reported (Fuller and Low, 2005; Klugman, 2002). This justifies the search for new drugs with different mechanisms of action. The bacteriolytic action of bacteriophage lysins enables the release of phage progeny from the bacterial sacculus. Purified pneumococcal phage lysin Cpl-1 has been used to successfully treat pneumococcal sepsis, endocarditis, meningitis, and pneumonia in rodent models (Entenza et al., 2005; Grandgirard et al., 2008; Loeffler et al., 2003). However, due to its short circulating half-life (~20.5 minutes) (Loeffler et al., 2003), optimal efficacy requires repeated injections or continuous infusion (Entenza et al., 2005). We recently showed that pre-dimerization of Cpl-1, which doubles the molecular weight of the enzyme, decreased its plasma clearance by a factor of ten (Resch et al., 2011). PEGylation (Veronese and Pasut, 2005) was shown to extend even more so the serum half-life of interferon-α2b from minutes to hours (Ramon et al., 2005) and of lysostaphin from 1 to 24 h (Walsh et al., 2003). Here we mono-PEGylated (Gaberc-Porekar et al., 2008; Walsh et al., 2003) Cpl-1 at various cysteine residues and determined the anti-pneumococcal activity of the resulting conjugates.
Materials and methods
Plasmid mini-prep kits were bought from Qiagen (Valencia, CA, USA). The QuickChange II Site-Directed Mutagenesis Kit was purchased from Stratagene (Cedar Creek, TX, USA). Mutagenic primers were obtained from Fischer Biotechnology (Pittsburgh, PA, USA) and DNA sequencing reactions were performed by Genewiz (South Plain, NJ, USA). DEAE-Sepharose, HiLoad 16/60 SuperdexTM 200 prep grade column, and PD-10 desalting columns were obtained from GE Healthcare Bio-Sciences Corp. (Piscataway, NJ, USA). Amicon Ultra centrifugal units Ultracel 30K were from Millipore (Carrigtwohill, Co. Cork, Ireland). Chemically competent Escherichia coli (E. coli) Max Efficiency DH5α cells and NuPAGE 4-12% Bis-Tris Gels were from Invitrogen (Carlsbad, CA, USA). Poly-ethylene glycol maleimide MW 10 kDa (PEG 10) and Y-shape poly-ethylene glycol maleimide MW 40 kDa (PEG 40) were purchased from Jenkem Technology (Allen, TX, USA). All other chemicals were from Sigma-Aldrich (Saint Louis, MO. USA).
Choosing PEGylation sites
List of mutagenic primers used in site-directed mutagenesis experiments
Forward mutagenic primer
Reverse mutagenic primer
5'-CGA CCT ATT TAA ACC CTA GCT TGT CTG CTC AAG TGG AGC AGT CAA ACC C-3'
5'-GGG TTT GAC TGC TCC ACT TGA GCA GAC AAG CT A GGG TTT AAA TAG GTC G-3'
5'-GTT TTT CCT TGA CAA CGT GCC TAT GTG C GT TAA ATA CCT TGT ATT GGA CTA CG-3'
5'-CGT AGT CCA ATA CAA GGT ATT TAA CGC A CA TAG GCA CGT TGT CAA GGA AAA AC-3'
5'-GTT AGA CGA TGA AGA AGA CTG CAA GCC AAA GAC CGC TGG A-3'
5'-TCC AGC GGT CTT TGG CTT GCA GTC TTC TTC ATC GTC TAA C-3'
5'-GGG TGG TGG TTC AGA CGA TG C AAT GGC AGT TTC CCT TA-3'
5'-TAA GGG AAA CTG CCA TTG CA T CGT CTG AAC CAC CAC CC-3'
5'-GTG GTG GTT CAG ACG AAA CAA TTG CAG TTT CCC TT-3'
5'-AAG GGA AAC TGC A AT TGT TTC GTC TGA ACC ACC AC-3'
5'-AAA TGG TAC TAC CTC AAG TG C AAC GGC GCA ATG GCG AC-3'
5'-GTC GCC ATT GCG CCG TTG CA C TTG AGG TAG TAC CAT TT-3'
5'-GTT GGG TGC TAG TCG GGT GC G AGT GGT ATT ATA TGG AC-3'
5'-GTC CAT ATA ATA CCA CTC GC A CCC GAC TAG CAC CCA AC-3'
5'-ACA CAA ACG GAG AGC TTG CAT G CA ATC CAA GTT TCA CGA AAG-3'
5'-CTT TCG TGA AAC TTG GAT TGC A TG CAA GCT CTC CGT TTG TGT-3'
Construction of plasmids carrying mutated Cpl-1 genes
Plasmids carrying the genes encoding for the Cpl-1 mutants included in this study were constructed as described elsewhere (Resch et al., 2011). Briefly, the plasmid encoding Cpl-1C45S was constructed using the QuickChange II Site-Directed Mutagenesis Kit with appropriate primers (Table 1) in order to introduce the desired mutation in the Cpl-1 gene originally carried on the pJML6 plasmid (Loeffler et al., 2003), following the manufacturer instructions. The plasmids encoding the mutant Cpl-1 proteins were further generated by the same approach (Table 1 for the list of primers) using the plasmid carrying the Cpl-1C45S gene as template. Plasmids containing the mutated genes were further transformed in E. coli DH5α following the manufacturer protocol. The presence of the mutations was confirmed by DNA sequencing.
Production and purification of Cpl-1 mutants
The production and purification of all proteins followed a protocol that has already been described for Cpl-1 (Loeffler and Fischetti, 2003) and Cpl-1 mutants (Resch et al., 2011). Briefly, E. coli DH5α cells were grown in Luria-Broth (LB) for 16 h aerobically at 37°C with agitation at 250 rpm. The cultures were diluted 10X (vol/vol) and allowed to grow for an additional 5 h in the same conditions. Protein expression was induced by the addition of 2% (w/v) lactose to the cultures. 16 h later, cells were pelleted, resuspended in phosphate buffer 50 mM, pH 7.4 (enzyme buffer), and sonicated on ice (three cycles of 30 sec at 70% power, Sonoplus, Bandelin Electronics, Berlin, Germany). Cell debris was pelleted by centrifugation (1 h at 4°C and 15,000 rpm) and supernatants were treated with 20 units (20 U) of DNAse I for 16 h at 4°C. 0.45 μm filtered supernatants were applied to a DEAE-Sepharose fast flow column previously equilibrated with enzyme buffer. Following a wash step with enzyme buffer containing 1 M NaCl, the enzymes were eluted with enzyme buffer containing 10% (w/v) choline. After extensive dialysis (cutoff 30,000 kDa) against enzyme buffer, the purified enzymes were concentrated using Ultracel 30K centrifugal filters and stored at -20°C.
PEGylation of Cpl-1 mutants
Purified mutant enzymes were reduced for 30 min at room temperature (RT) in enzyme buffer containing 10 mM dithiotreitol (DTT), and desalted on PD-10 columns previously equilibrated with enzyme buffer. Protein concentrations were adjusted to 1 mg/ml and either PEG maleimide MW 10,000 kDa (PEG 10K) or Y-shaped PEG Maleimide MW 40,000 kDa (PEG 40K) was added (1/25 and 1/10 mol protein/mol PEG for PEG 10K and 40K, respectively). After a 15 min. incubation period at RT with constant gentle agitation, the excess of unbound PEG was removed by applying the mixtures to a DEAE-Sepharose column previously equilibrated with enzyme buffer. PEGylated conjugates and residual fractions of non-PEGylated enzymes were eluted with enzyme buffer containing 10% (w/v) choline, and then purified by gel filtration on a HiLoad 16/60 Superdex™ 200 prep grade column pre-equilibrated in enzyme buffer. Fractions containing the purified PEGylated enzymes were pooled, concentrated using Ultracel 30K centrifugal filters and stored at -20°C until further use.
In vitro killing assay
The killing assay was performed using S. pneumoniae strain DCC1490 (serotype 14) obtained from A. Tomasz and has been described elsewhere (Loeffler and Fischetti, 2003; Loeffler et al., 2001). Briefly, DCC1490 was grown to log-phase in aerobic conditions without agitation (OD595 nm of 0.3) in brain heart infusion (BHI) at 37°C. After centrifugation and re-suspension of DCC1490 in enzyme buffer at a concentration of 109 cfu/ml, serial dilutions of enzymes were added to the cells. Reaction kinetics were obtained by measuring the decrease of the OD595 nm at 37°C over a period of 28 min. in a EL808 microplates reader (Biotek Instruments Gmbh, Luzern, Switzerland).
While introducing cysteines at several sites on Cpl-1 did not alter its bactericidal activity, PEGylation on these residues totally abrogated it. This might be related to the complex structure and mode of action of the enzyme, which makes it susceptible to bulky adducts. Cpl-1 has a C-terminal domain that mediates binding to choline in the cell wall for adequate positioning of the N-terminal catalytic domain to cleave its substrate (Diaz et al., 1990; Perez-Dorado et al., 2007). Optimal positioning may also depend on enzyme C-terminus dimerization, as described for the pneumococcal autolysin LytA (Romero et al., 2007).
Susceptibility to PEG-related hindrance is supported by the fact that PEGylation on the hinge region (C194) inhibited activity, in spite of the fact that this region is independent of both the binding and active domains. Adding a bulky adduct to this location is thought to affect flexibility of the hinge and interfere with optimal orientation of the enzyme into the wall.
The present results do not preclude that PEGylation at other sites or with different types of PEG could possibly extend Cpl-1 half-life with less detrimental effect on its bactericidal activity. However, we believe that this work highlights the fact that cysteine-specific PEGylation could be unsuitable for a large set of enzybiotics with a similar architecture.
This work was supported by a Marie Curie grant MOIF-039101 from the European Union to G.R. We thank Alexander Tomasz for the S. pneumoniae strain DCC1490 and Shawna E. McCallin for reading of the manuscript.
- Abramoff MD, Magalhaes PJ, Ram SJ: Image Processing with ImageJ. Biophotonic Int 2004, 11: 36–42.Google Scholar
- Diaz E, Lopez R, Garcia JL: Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes. Proc Natl Acad Sci USA 1990, 87: 8125–8129. 10.1073/pnas.87.20.8125PubMed CentralPubMedView ArticleGoogle Scholar
- Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P: Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005, 49: 4789–4792. 10.1128/AAC.49.11.4789-4792.2005PubMed CentralPubMedView ArticleGoogle Scholar
- Fuller JD, Low DE: A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005, 41: 118–121. 10.1086/430829PubMedView ArticleGoogle Scholar
- Gaberc-Porekar V, Zore I, Podobnik B, Menart V: Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 2008, 11: 242–250.PubMedGoogle Scholar
- Grandgirard D, Loeffler JM, Fischetti VA, Leib SL: Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 2008, 197: 1519–1522. 10.1086/587942PubMedView ArticleGoogle Scholar
- Jacobs MR: Streptococcus pneumoniae : epidemiology and patterns of resistance. The American journal of medicine 2004,117(Suppl 3A):3S-15S.PubMedGoogle Scholar
- Klugman KP: Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 2002, (Suppl 36):3s-8s.Google Scholar
- Loeffler JM, Djurkovic S, Fischetti VA: Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003, 71: 6199–6204. 10.1128/IAI.71.11.6199-6204.2003PubMed CentralPubMedView ArticleGoogle Scholar
- Loeffler JM, Fischetti VA: Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 2003, 47: 375–377. 10.1128/AAC.47.1.375-377.2003PubMed CentralPubMedView ArticleGoogle Scholar
- Loeffler JM, Nelson D, Fischetti VA: Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001, 294: 2170–2172. 10.1126/science.1066869PubMedView ArticleGoogle Scholar
- Perez-Dorado I, Campillo NE, Monterroso B, Hesek D, Lee M, Paez JA, Garcia P, Martinez-Ripoll M, Garcia JL, Mobashery S, Menendez M, Hermoso JA: Elucidation of the molecular recognition of bacterial cell wall by modular pneumococcal phage endolysin CPL-1. J Biol Chem 2007, 282: 24990–24999. 10.1074/jbc.M704317200PubMedView ArticleGoogle Scholar
- Ramon J, Saez V, Baez R, Aldana R, Hardy E: PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm Res 2005, 22: 1374–1386.PubMedView ArticleGoogle Scholar
- Resch G, Moreillon P, Fischetti VA: A Stable Phage Lysin (Cpl-1) Dimer with Increased Anti-Pneumococcal Activity and Decreased Plasma Clearance. Int Journal of Antimicrobial Agents 2011, in press.Google Scholar
- Romero P, Lopez R, Garcia E: Key role of amino acid residues in the dimerization and catalytic activation of the autolysin LytA, an important virulence factor in Streptococcus pneumoniae . J Biol Chem 2007, 282: 17729–17737. 10.1074/jbc.M611795200PubMedView ArticleGoogle Scholar
- Veronese FM, Pasut G: PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10: 1451–1458. 10.1016/S1359-6446(05)03575-0PubMedView ArticleGoogle Scholar
- Walsh S, Shah A, Mond J: Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol. Antimicrob Agents Chemother 2003, 47: 554–558. 10.1128/AAC.47.2.554-558.2003PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.